Strategic Partnerships Alpha Tau Medical is pursuing strategic collaborations to bring Alpha DaRT therapy to the US market, including a Tolmar partnership and multi-site EU trials, signaling a potential entry path for US-based distributors, oncology clinics, and hospital networks seeking novel radiotherapy options.

Clinical Expansion Active and expanding clinical trial footprint across 55 leading cancer centers worldwide with recent presentations at major conferences, indicating growing demand for Alpha DaRT data and opportunities to engage clinical trial sites for site-based sponsorships, Investigator Initiated Trials, and data generation collaborations.

Targeted Indications Strong focus on solid tumors including pancreatic, head and neck, and urological cancers with demonstrated combination potential with immunotherapies like pembrolizumab, suggesting cross-sell opportunities to oncology centers treating these indications and to payers seeking differentiated outcomes.

Operational Readiness Tech stack and disposable applicator approach imply relatively low capital expenditure for adopters and simpler integration for clinical teams, creating a sales angle around rapid deployment, minimal facility upgrades, and compatibility with existing radiation oncology workflows.

Financial Capacity sizable revenue and substantial funding runway position Alpha Tau to support large-scale trials and market launch activities, enabling conversations with potential distributors, contract manufacturers, and health systems about scale, pricing models, and long-term collaborations.